Gastroenterology Insights (Nov 2022)

Clinical and Safety Evaluation of Liv.52 in Alcoholic Liver Disease: A Review

  • Subramanian Ganesh,
  • Neeraj Joshi,
  • Mukesh Kumar Jain,
  • Lokendra Sharma,
  • Anish Desai,
  • Mohamed Rafiq,
  • Uddagiri Venkanna Babu,
  • Rajesh Kumawat

DOI
https://doi.org/10.3390/gastroent13040037
Journal volume & issue
Vol. 13, no. 4
pp. 377 – 386

Abstract

Read online

Alcoholic liver disease (ALD) has been a growing concern in developed and developing nations. Oxidative stress and lipid peroxidation are the most common cause of the development and progression of ALD. Due to paucity in the number and efficacy of hepatoprotective drugs currently available, and with the easy availability of natural therapy and herbal medicines, ALD is managed using a combination of pharmaceutical interventions and herbal medications. However, the effectiveness of these hepatoprotectives is controversial. Preclinical and clinical studies have demonstrated that Liv.52 modulates the lipotropic activity of hepatocytes, reduces inflammation, enhances alcohol and acetaldehyde metabolism, and protects the hepatic parenchyma by restoring the antioxidant levels of hepatocytes. Clinical studies further support that there is improvement in the subjective symptoms of patients as well as improvements in liver function test parameters. Studies suggest that Liv.52 is well tolerated and has no reported side effects.

Keywords